Sandeep Das, MD, MPH, reports on collecting data about CV disease and COVID-19. Navigation tips, please click here.
Science News
Scenario Analyses of Lifetime Cost-Effectiveness of Icosapent Ethyl in REDUCE-IT

Zugui Zhang | Christina Care Health System, Newark, Deleware

  • RESULTS: Multiple scenario analyses found lifetime cost-effectiveness of icosapent ethyl ($4.64/day) compared to standard care.
  • Zhang's Abstract
Patient-Reported Outcomes, Resource Utilization, and Health Care Expenditures Across the 3 Major Atherosclerotic Diseases: The Medical Expenditure Panel Survey (meps)

Martin Tibuakuu | St. Luke's Hospital, Ballwin, Missouri

  • RESULTS: Compared to CAD, stroke and PAD were associated with lower use of guideline-directed preventive therapies, highlighting a missed opportunity for secondary ASCVD prevention in these patients.
  • Tibuakuu's Abstract
Impacts of the Million Hearts® Cardiovascular Disease Risk Reduction Model on the Initiation or Intensification of Statins and Anti-Hypertensive Medications: A Pragmatic, Cluster-Randomized Trial

G. Greg Peterson | Mathematica Policy Research, Washington, DC

  • RESULTS: Use of CVD medications significantly improved with the Million Hearts® model, especially in high-risk participants and increased provider awareness of risk.
  • Peterson's Abstract
Social Determinants of Health and Participant Retention in a Disparities Study and Primary Care: Findings From the Hypertension and Values (hyvalue) Trial

Kamal Henderson | Rocky Mountain VA Medical Center, Denver, Colorado

  • RESULTS: Higher social determinants of health levels associated with less research study retention.
  • Henderson's Abstract
Patient-Reported Versus Physician-Estimated Angina in Patients Undergoing PCI

Andy T. Tran | Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City, Missouri

  • RESULTS: Discordance noted between patient-reported and physician estimates of angina. Tools that include the patient's outcome measures may help select those who will have QOL benefits after PCI.
  • Tran's Abstract